Literature DB >> 23656728

Transfusion suppresses erythropoiesis and increases hepcidin in adult patients with β-thalassemia major: a longitudinal study.

Sant-Rayn Pasricha1, David M Frazer, Donald K Bowden, Gregory J Anderson.   

Abstract

β-Thalassemia major causes ineffective erythropoiesis and chronic anemia and is associated with iron overload due to both transfused iron and increased iron absorption, the latter mediated by suppression of the iron-regulatory hormone hepcidin. We sought to determine whether, in β-thalassemia major, transfusion-mediated inhibition of erythropoiesis dynamically affects hepcidin. We recruited 31 chronically transfused patients with β-thalassemia major and collected samples immediately before and 4 to 8 days after transfusion. Pretransfusion hepcidin was positively correlated with hemoglobin and ferritin and inversely with erythropoiesis. The hepcidin-ferritin ratio indicated hepcidin was relatively suppressed given the degree of iron loading. Posttransfusion, hemoglobin and hepcidin increased, and erythropoietin and growth differentiation factor-15 decreased. By multiple regression, pre- and posttransfusion hepcidin concentrations were both associated positively with hemoglobin, inversely with erythropoiesis, and positively with ferritin. Although men and women had similar pretransfusion hemoglobin, men had significantly increased erythropoiesis and lower hepcidin, received a lower transfusion volume per liter blood volume, and experienced a smaller posttransfusion reduction in erythropoiesis and hepcidin rise. Age of blood was not associated with posttransfusion hemoglobin or ferritin change. Hepcidin levels in patients with β-thalassemia major dynamically reflect competing influences from erythropoiesis, anemia, and iron overload. Measurement of these indices could assist clinical monitoring.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23656728     DOI: 10.1182/blood-2012-12-471441

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  51 in total

1.  Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of β-thalassemia.

Authors:  Léon Kautz; Grace Jung; Xin Du; Victoria Gabayan; Justin Chapman; Marc Nasoff; Elizabeta Nemeth; Tomas Ganz
Journal:  Blood       Date:  2015-08-14       Impact factor: 22.113

2.  Erythropoiesis is not equally suppressed in transfused males and females with β-thalassemia major: are there clinical implications?

Authors:  Greg Hapgood; Timothy Walsh; Ronit Cukierman; Eldho Paul; Ken Cheng; Donald K Bowden
Journal:  Haematologica       Date:  2015-04-24       Impact factor: 9.941

3.  Replacing the suppressed hormone: toward a better treatment for iron overload in β-thalassemia major?

Authors:  Domenico Girelli; Fabiana Busti
Journal:  Haematologica       Date:  2020-07       Impact factor: 9.941

Review 4.  Transfusion related morbidity in premature babies: Possible mechanisms and implications for practice.

Authors:  Keith James Collard
Journal:  World J Clin Pediatr       Date:  2014-08-08

5.  A variant erythroferrone disrupts iron homeostasis in SF3B1-mutated myelodysplastic syndrome.

Authors:  Sabrina Bondu; Anne-Sophie Alary; Carine Lefèvre; Alexandre Houy; Grace Jung; Thibaud Lefebvre; David Rombaut; Ismael Boussaid; Abderrahmane Bousta; François Guillonneau; Prunelle Perrier; Samar Alsafadi; Michel Wassef; Raphaël Margueron; Alice Rousseau; Nathalie Droin; Nicolas Cagnard; Sophie Kaltenbach; Susann Winter; Anne-Sophie Kubasch; Didier Bouscary; Valeria Santini; Andrea Toma; Mathilde Hunault; Aspasia Stamatoullas; Emmanuel Gyan; Thomas Cluzeau; Uwe Platzbecker; Lionel Adès; Hervé Puy; Marc-Henri Stern; Zoubida Karim; Patrick Mayeux; Elizabeta Nemeth; Sophie Park; Tomas Ganz; Léon Kautz; Olivier Kosmider; Michaëla Fontenay
Journal:  Sci Transl Med       Date:  2019-07-10       Impact factor: 17.956

Review 6.  Low hemoglobin deferral in blood donors.

Authors:  Alan E Mast
Journal:  Transfus Med Rev       Date:  2013-11-12

Review 7.  Modulation of hepcidin as therapy for primary and secondary iron overload disorders: preclinical models and approaches.

Authors:  Paul J Schmidt; Mark D Fleming
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-18       Impact factor: 3.722

Review 8.  The pathophysiology and pharmacology of hepcidin.

Authors:  Piotr Ruchala; Elizabeta Nemeth
Journal:  Trends Pharmacol Sci       Date:  2014-02-17       Impact factor: 14.819

9.  Progesterone receptor membrane component-1 regulates hepcidin biosynthesis.

Authors:  Xiang Li; David K Rhee; Rajeev Malhotra; Claire Mayeur; Liam A Hurst; Emily Ager; Georgia Shelton; Yael Kramer; David McCulloh; David Keefe; Kenneth D Bloch; Donald B Bloch; Randall T Peterson
Journal:  J Clin Invest       Date:  2015-12-14       Impact factor: 14.808

Review 10.  Retinal abnormalities in β-thalassemia major.

Authors:  Devang L Bhoiwala; Joshua L Dunaief
Journal:  Surv Ophthalmol       Date:  2015-08-29       Impact factor: 6.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.